T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA
Clinical trials for T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA trials appear
Sign up with your email to follow new studies for T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to tame rare blood cancers
Disease control Recruiting nowThis early-phase trial tests two drugs, ruxolitinib and duvelisib, together in people whose T- or NK-cell lymphoma has come back or stopped responding to treatment. The main goal is to find the safest dose of duvelisib when combined with a fixed dose of ruxolitinib. About 70 part…
Matched conditions: T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New hope for rare leukemia: ruxolitinib trial launches
Disease control Recruiting nowThis phase 2 trial tests whether the drug ruxolitinib can shrink tumors in 30 adults with T-cell large granular lymphocyte leukemia, a rare blood cancer. Ruxolitinib works by blocking enzymes that cancer cells need to grow. The study will measure how many patients respond to trea…
Matched conditions: T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA
Phase: PHASE2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC